Cerebellar Disorders
Methodology & AI Transparency ⓘ
Cerebellar Disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: When you play the piano or hit a tennis ball you are activating the cerebellum.
- 2 Real-world patient consensus: Federal ICD-10-CM code C43.7 categorizes Cerebellar Disorders under Cancer, Oncology & Supportive Care.
- 3 Typical cash cost range: Clinicians assessing Cerebellar Disorders focus on angiogenesis [Cerebellar Disorders C43.7] and targeted history.
- 4 Top reported side effects / signs: Key Cancer & Oncology biomarkers for Cerebellar Disorders (C43.7): Pathology / Molecular in Cerebellar Disorders (C43.7: Genomic Staging) & Complete Blood Count in Cerebellar Disorders (C43.7: (ANC, Hemoglobin, Platelets)) (Safe hematologic reserve (C43.7)).
Ask our AI Specialists anything about Cerebellar Disorders
What Is Cerebellar Disorders?
When you play the piano or hit a tennis ball you are activating the cerebellum. The cerebellum is the area of the brain that controls coordination and balance. Problems with the cerebellum include: Cancer Genetic disorders Ataxias - failure of muscle control in the arms and legs that result in movement disorders Degeneration - disorders caused by brain cells decreasing in size or wasting away Treatment of cerebellar disorders depends on the cause. In some cases, there is no cure but treatment may help with symptoms.
Pathophysiology, Underlying Causes & Clinical Presentation
Cerebellar Disorders (C43.7) alters cancer & oncology homeostasis through angiogenesis [Cerebellar Disorders C43.7]; Cross-referenced with NIH MeSH (Cerebellar Diseases), clinical remission targets Complete Blood Count in Cerebellar Disorders (C43.7: (ANC, Hemoglobin, Platelets)) within Safe hematologic reserve (C43.7).
Common Symptoms & Clinical Signs
- • Ataxias - failure of muscle control in the arms and legs that result in movement disorders
- • Degeneration - disorders caused by brain cells decreasing in size or wasting away
- • Presentation of Cerebellar Disorders (C43.7): abnormality detected early in Cerebellar Disorders (C43.7: on age-appropriate screening)
- • Secondary Cerebellar Disorders clinical sign: persistent painless lump, in Cerebellar Disorders (C43.7: non-healing ulcer/mole change,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cerebellar Disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C43.7 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Cerebellar Disorders (C43.7: Genomic Staging) | Guideline-concordant surveillance (C43.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Cerebellar Disorders (C43.7: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C43.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Cerebellar Disorders (C43.7: Organ Function Panel) | Preserved renal/hepatic clearance (C43.7) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cerebellar Disorders
Treatment selection for Cerebellar Disorders depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cerebellar Disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of palbociclib plus letrozole on patient-reported health-related quality: What a 444-Participant Study Found This extended follow-up analysis of PROs in PALOMA-2 shows continued QoL maintenance for patients with ER+/HER2- mBC receiving long-term palbociclib plus letrozole treatment. ESMO open • 2025-04-15 • Phase III Randomized Trial | N = 444 | 93/100 | PMID 40107156 ↗ |
| Can This Approach Help? Inside the Latest Research on Body weight loss as a prognostic and predictive factor in previously treated In TAGS, early BWL was a strong negative prognostic factor for OS in patients with mGC/GEJC receiving third- or later-line treatment. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association • 2023-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37106214 ↗ |
| Can This Approach Help? Inside the Latest Research on Ibrutinib added to standard conditioning and as maintenance therapy following There were 4 fatalad verse events in the ibrutinib arm due to infection. Leukemia & lymphoma • 2025-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40632607 ↗ |
| New Insights on Effect of Nurse Navigators in Digital Remote Monitoring in Cancer Care: Case: What a 559-Participant Study Found This study shows the central role of NNs in making DRM effective. Journal of medical Internet research • 2025-03-28 • Phase III Randomized Trial | N = 559 | 87/100 | PMID 40153795 ↗ |
| New Insights on Meaningful change threshold estimation for the non-small cell lung cancer symptom: What a 246-Participant Study Found This study provides the first worsening and improvement estimates of MWPC, MIC, and MID for NSCLC-SAQ total and symptom scores. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation • 2025-04-15 • Phase III Randomized Trial | N = 246 | 82/100 | PMID 39847268 ↗ |
Cerebellar Disorders Patient Community & “People Like Me” Threads
Filter Cerebellar Disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.